Cannabis as an Anthroposophic Herb 

Michelle Sexton, ND  

The Center for the Study of Cannabis and Social  Policy, Seattle, WA 


Cannabis and cannabinoids can fall into all three classes: adaptogenic, amphoteric and biphasic, which indicates that there is no one ideal dose or ratio oÿ cannabinoids. This is largely due to the effects of Cannabis being dependent upon the state  of the user. The endocannabinoid  system plays a major role in stress adaptation, at the molecular level.  


Cannabis as an adaptogen has the potential not only to promote biochemical modification, but also to bring homeostasis psychologically, by  working to help adaptation to discontinuities and  dislocations associated with modernity.  By addressing the whole person: body, mind, and  spirit.  


Cannabis transcends the molecular medicine model and works by an orthomolecular  mechanism and may be considered to be “anthroposophic medicine”.   Cannabis is adaptogenic by helping to integrate perspective, release resistance, and balance the  biochemistry when used as part oÿ a comprehensive and inteĀrated healthcare model in an  attempt to “treat the cause”. 

Michelle Sexton, ND is one of the lead authors of the American Herbal Pharmacopoeia Cannabis  MonoĀraph 

According to Dr Sexton, “This monograph is historic in that it is the first normal pharmacopoeial monograph on cannabis developed in the US in more than 70 years. The first monoĀraph was  introduced into the United States Pharmacopoeia in 1850 and was removed ÿrom the 12th  edition in 1942. ConsiderinĀ the widespread use oÿ cannabis, it is important ÿor there to be  quality control Āuidance whether used ÿor medicinal or non-medicinal purposes.” 

AccordinĀ to Steph Sherer, executive director oÿ ASA, “The AHP monoĀraph creates much needed  quality assurance standards ÿor States that have medical access laws. The adoption oÿ these  standards will create confidence in the quality and reliability oÿ cannabis therapies ÿor  patients and their physicians.” 

The various bodies oÿ inÿormation contained in the monoĀraph include: standards ÿor identification,  quality, and purity; cultivation and processinĀ Āuidance; constituent profile; and a variety oÿ  analytical methodoloĀies ÿor the identification oÿ the plant as well as quantitation oÿ specific  cannabinoids. Much oÿ this inÿormation was developed in collaboration with numerous  researchers at the University oÿ Mississippi (UMiss) under the Āuidance oÿ Dr. Mahmoud  ElSohly, proÿessor oÿ pharmaceutics and one oÿ this country’s ÿoremost cannabis experts.  UMiss is the only ÿederally leĀal source oÿ medical marijuanain the US and they have been  analyzinĀ their own cultivated material, as well as products seized by the DruĀ Enÿorcement  Administration (DEA) ÿor more than 30years. They are amonĀ the most expert in the world on  all thinĀs cannabis. 

The inÿormation provided in the monoĀraph will be oÿ value to a wide ranĀe oÿ those involved in the  medical use oÿ cannabis includinĀ Ārowers, careĀivers,patients, practitioners, analytical labs,  state reĀulators, and researchers. This pharmacopoeial monoĀraph will be ÿollowed by a  Therapeutic Compendium, which will present a comprehensive review oÿ the world’s historical  and scientific use oÿ cannabis.”